Ibrutinib in the News

Recently, the big news in our CLL universe is about Ibrutinib. You may have read about it in  the Forbes article,  The Wild Story Behind A Promising Experimental Cancer Drug, on WebMD blog, or in a local media article , e.g., New Drug to Help Battle Cancer.

I recommend that those interested in this news about Ibrutinib read the  post,  History of Ibrutinib, on Dr. Sharman’s CLL & Lymphoma Blog. He concludes,

For a drug likely to cost nearly $90k per year (my guess only) – insurance will likely look quite closely at who is receiving it.  While CLL patients will greet the approval – it may still take a while for them to access the medicine.  That is why getting involved in research studies is so important!!!!

For more Ibrutinib insights, check out these other related posts by Dr. Sharman.

April 22, 2013

Blood Cancers Update:

Breakthrough Drug Ibrutinib Continues to Impress in Chronic Lymphocytic Leukemia


Source: Cure Magazine Newsletter

April 8, 2013

Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration


About Webmaster

Webmaster for gotCLL.com is a retired educator who has worked for more than 50 years in secondary, higher, medical, and life-long learning education.
This entry was posted in Clinical Studies, New Advances, Oncologist / Hematologist. Bookmark the permalink.

5 Responses to Ibrutinib in the News

  1. T says:

    I am in the Phase 3 trial and taking Ibrutinib. It has done wonders for me in only 6 months. I hope the cost is something that insurance will be able to pay for al that need it. Once the trial is finished I am not sure if I will be left on the drug or not. I have asked this several times and do not get straight answer. I was partially relapsed with laRGE growing nodes, unmutated, t12+11q. In 6 months it knocked the nodes way back. Blood is normal now. This stuff is the real deal!!!! At least that is the way it looks now.

    • Webmaster says:

      That’s great news. Thanks for sharing your experiences with Ibrutinib.

      • Gerald Goldstein says:

        Thanks for your great news. I hope the treatment keeps you in remission and that you are able to obtain the drug when the study ends. I would check the protocol or consent papers that you signed, which should spell out whether or not you will receive the drug when the study is over.

  2. Webmaster says:


    Thanks for your reply.

    For those interested in the Cure article, here’s a link: http://www.curetoday.com/index.cfm/fuseaction/news.showNewsArticle/id/13/news_id/3687


  3. Gerald Goldstein says:

    I liked your blog report. There is also information about Ibrutinib and Dr. Wiestner and about the clinical trial he is running at NIH in Cure dated April 8, 2013. I have been diagnosed with CLL unmutated gene 7 years ago. Unfortunately I need to be treated. I am trying to get into the NIH clinical trial program. Keep up the good work.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s